Recombinant Anti-FAK (phospho Y861) antibody [EP841Y] (ab81293)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP841Y] to FAK (phospho Y861)
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-FAK (phospho Y861) antibody [EP841Y]
See all FAK primary antibodies -
Description
Rabbit monoclonal [EP841Y] to FAK (phospho Y861) -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Jurkat cell; NIH/3T3; C6 (Rat glial tumor glial cell) lysates treated with pervanadate.
-
General notes
The production method for this product has been changed from hybridoma to recombinant on 15th April 2024.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 59% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP841Y -
Isotype
IgG -
Research areas
Associated products
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab81293 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/5000. Predicted molecular weight: 119 kDa.
|
Notes |
---|
WB
1/5000. Predicted molecular weight: 119 kDa. |
Target
-
Function
Non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis. Activated by tyrosine-phosphorylation in response to either integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or via LDL receptor occupancy. Microtubule-induced dephosphorylation at Tyr-397 is crucial for the induction of focal adhesion disassembly. Plays a potential role in oncogenic transformations resulting in increased kinase activity. -
Tissue specificity
Expressed in all organs tested, in lymphoid cell lines, but most abundantly in brain. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. FAK subfamily.
Contains 1 FERM domain.
Contains 1 protein kinase domain. -
Domain
The first Pro-rich domain interacts with the SH3 domain of CRK-associated substrate (BCAR1) and CASL.
The carboxy-terminal region is the site of focal adhesion targeting (FAT) sequence which mediates the localization of FAK1 to focal adhesions. -
Post-translational
modificationsPhosphorylated on 6 tyrosine residues upon activation. Microtubule-induced dephosphorylation at Tyr-397 could be catalyzed by PTPN11 and regulated by ZFYVE21. Dephosphorylated by PTPN11 upon EPHA2 activation by its ligand EFNA1. -
Cellular localization
Cell junction > focal adhesion. Cell membrane. Constituent of focal adhesions. - Information by UniProt
-
Database links
- Entrez Gene: 5747 Human
- Entrez Gene: 14083 Mouse
- Entrez Gene: 25614 Rat
- Omim: 600758 Human
- SwissProt: Q05397 Human
- SwissProt: P34152 Mouse
- SwissProt: O35346 Rat
- Unigene: 395482 Human
see all -
Alternative names
- FADK 1 antibody
- FADK antibody
- FAK related non kinase polypeptide antibody
see all
Images
-
All lanes : Anti-FAK (phospho Y861) antibody [EP841Y] (ab81293) at 1/1000 dilution
Lane 1 : Untreated C6 (Rat glial tumor glial cell) whole cell lysate
Lane 2 : C6 treated with 10mM pervanadate for 60mins whole cell lysate
Lane 3 : C6 treated with 10mM pervanadate for 60mins whole cell lysate, then the membrane treated with phosphatase
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 119 kDa
Exposure time: 20 secondsBlocking and diluting buffer and concentration: 5% NFDM/TBST.
ab181602 was used as a GAPDH loading control.
-
All lanes : Anti-FAK (phospho Y861) antibody [EP841Y] (ab81293) at 1/1000 dilution
Lane 1 : Untreated NIH/3T3 (Mouse embryonic fibroblast) whole cell lysate
Lane 2 : NIH/3T3 treated with 10mM pervanadate for 60mins whole cell lysate
Lane 3 : NIH/3T3 treated with 10mM pervanadate for 60mins whole cell lysate, then the membrane treated with phosphatase
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 119 kDa
Exposure time: 5 secondsBlocking and diluting buffer and concentration: 5% NFDM/TBST.
ab181602 was used as a GAPDH loading control.
-
All lanes : Anti-FAK (phospho Y861) antibody [EP841Y] (ab81293) at 1/1000 dilution
Lane 1 : Untreated Jurkat (Human T cell leukemia T lymphocyte) whole cell lysate
Lane 2 : Jurkat treated with 10mM pervanadate for 30mins whole cell lysate
Lane 3 : Jurkat treated with 10mM pervanadate for 30mins whole cell lysate, then the membrane treated with phosphatase
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 119 kDa
Exposure time: 20 secondsBlocking and diluting buffer and concentration: 5% NFDM/TBST.
ab181602 was used as a GAPDH loading control.
Datasheets and documents
-
SDS download
-
Datasheet download
References (5)
ab81293 has been referenced in 5 publications.
- Jiang K et al. Exosome-derived ENO1 regulates integrin a6ß4 expression and promotes hepatocellular carcinoma growth and metastasis. Cell Death Dis 11:972 (2020). PubMed: 33184263
- Zhang YL et al. Integrin a9 Suppresses Hepatocellular Carcinoma Metastasis by Rho GTPase Signaling. J Immunol Res 2018:4602570 (2018). PubMed: 29951557
- Luo X et al. Bioinformatics analysis of microarray profiling identifies the mechanism of focal adhesion kinase signalling pathway in proliferation and apoptosis of breast cancer cells modulated by green tea polyphenol epigallocatechin 3-gallate. J Pharm Pharmacol 70:1606-1618 (2018). PubMed: 30187481
- Xu Z et al. Integrin ß1 is a critical effector in promoting metastasis and chemo-resistance of esophageal squamous cell carcinoma. Am J Cancer Res 7:531-542 (2017). PubMed: 28401009
- Wu J et al. AURKA promotes cell migration and invasion of head and neck squamous cell carcinoma through regulation of the AURKA/Akt/FAK signaling pathway. Oncol Lett 11:1889-1894 (2016). PubMed: 26998095